Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, Open-label, Phase 3 trial

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 149-158

  Gravis, Gwenaelle ^a   Fizazi, Karim ^b   Joly, Florence ^c   Oudard, Stéphane ^d   Priou, Franck ^e   Esterni, Benjamin ^a   Latorzeff, Igor ^f   Delva, Remy ^g   Krakowski, Ivan ^h   Laguerre, Brigitte ⁱ   Rolland, Fréderic ^j   Théodore, Christine ^k   Deplanque, Gael ^l   Ferrero, Jean Marc ^m   Pouessel, Damien ⁿ   Mourey, Loïc ^o   Beuzeboc, Philippe ^p   Zanetta, Sylvie ^q   Habibian, Muriel ^r   Berdah, Jean François ^s   Dauba, Jerome ^t   Baciuchka, Marjorie ^u   Platini, Christian ^v   Linassier, Claude ^w   Labourey, Jean Luc ^x   Machiels, Jean Pascal ^y   El Kouri, Claude ^z   Ravaud, Alain ^aa   Suc, Etienne ^ab   Eymard, Jean Christophe ^ac   Hasbini, Ali ^ad   Bousquet, Guilhem ^ae   Soulie, Michel ^af   more..

^a INSTITUT PAOLI CALMETTES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CHU CÔTE DE NACRE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e Medical Oncology   (France)

^f CLINIQUE PASTEUR   (France)

^g CENTRE PAUL PAPIN   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ CENTRE EUGÈNE MARQUIS   (France)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k FOCH HOSPITAL   (France)

^l SAINT JOSEPH HOSPITAL   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ CENTRE VAL D AURELLE   (France)

^o INSTITUT CLAUDIUS REGAUD   (France)

^p INSTITUT CURIE   (France)

^q CENTRE GEORGES FRANÇOIS LECLERC   (France)

^r UNICANCER   (France)

^s Medical Oncology   (France)

^t Hôpital Layné   (France)

^u TIMONE HOSPITAL   (France)

^v Centre Régional Hospitalier Metz Thionville   (France)

^w CHU BRETONNEAU   (France)

^x DUPUYTREN UNIVERSITY HOSPITAL   (France)

^y CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^z Centre Catherine de Sienne   (France)

^aa HÔPITAL SAINT ANDRÉ   (France)

^ab Clinique Saint Jean Languedoc   (France)

^ac INSTITUT JEAN GODINOT   (France)

^ad Medical Oncology   (France)

^ae SAINT LOUIS HOSPITAL   (France)

^af CHU RANGUEIL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ANTHRACYCLINE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CABAZITAXEL; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DTS 201; EFAVIRENZ; ENZALUTAMIDE; ENZASTAURIN; ETOPOSIDE; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; IPILIMUMAB; MASITINIB; NAVELBINE; NINTEDANIB; ORTERONEL; PACLITAXEL; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; SAGOPILONE; SILTUXIMAB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZIBOTENTAN;

ADULT; AGED; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANOREXIA; ARTICLE; BELGIUM; BONE METASTASIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; FEBRILE NEUTROPENIA; FRANCE; GYNECOMASTIA; HOT FLUSH; HUMAN; INFECTION; LIBIDO DISORDER; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; ORCHIECTOMY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84873095322     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70560-0     Document Type: Article

References (29)

1. Roehrborn CG, Black LK The economic burden of prostate cancer. BJU Int 2011, 108:806-813.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parking DM GLOBOCAN 2008 (version 1.2) 2010, International Agency for Research on Cancer, Lyon.
3. SEER stat fact sheets: prostate Surveillance Epidemiology and End Results, (accessed May 21, 2012). http://seer.cancer.gov/statfacts/html/prost.html.
4. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. J Urol 1997, 158:1623-1624. The Medical Research Council Prostate Cancer Working Party Investigators Group.
5. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007, 25:1596-1605.
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
7. Smaletz O, Scher HI Outcome predictions for patients with metastatic prostate cancer. Semin Urol Oncol 2002, 20:155-163.
8. Glass TR, Tangen CM, Crawford ED, Thompson I Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003, 169:164-169.
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
11. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
13. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
14. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
15. Grambsch PT, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
16. Schemper M, Wakounig S, Heinze G The estimation of average hazard ratios by weighted Cox regression. Stat Med 2009, 28:2473-2489.
17. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009, 27:2450-2456.
18. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14:2763-2767.
19. Hussain MT, Higano CM, Crawford CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 4.
20. Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012, 188:1164-1169.
21. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008, 26:5936-5942.
22. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000, 86:675-680.
23. Fizazi K, Lesaunier F, Delva R, et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012, 48:209-217.
24. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011, 29:2040-2045.
25. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30:1534-1540.
26. Rathkopf D, Carducci MA, Morris MJ, et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 2008, 26:2959-2965.
27. Hussain A, Dawson N, Amin P, et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005, 23:2789-2796.
28. Taplin ME, Xie W, Bubley GJ, et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006, 24:5408-5413.
29. Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 2010, 28:4562-4567.